Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced the proposed issuance of shares and the issuance of stock options.
Under shares for debt agreements, the Company will issue an aggregate of 406,250 common shares of the Company ("Shares") to directors of the Company at a deemed price of $0.06 per Share. The Shares will be provided to settle debt for service expenses and will be subject to a four month hold period in accordance with applicable securities laws.
The Company also granted 62,500 stock options to a director of the Company, each option exercisable at $0.06 per Share for five years from the date of grant and vesting immediately. The options are subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com